{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:59:43Z","timestamp":1793401183598,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40123-025-01305-w","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:18:55Z","timestamp":1770142735000},"page":"1069-1082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["One-Year Real-World Outcomes of Aflibercept 8\u00a0mg in Treatment-Na\u00efve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-7867","authenticated-orcid":false,"given":"Gabriela","family":"Grimaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus G.","family":"Garweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel B.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Peyla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Cristina","family":"De Oliveira Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahm","family":"Spitznagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice M.","family":"Kitay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Gabathuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Zweifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaika Mihal","family":"Kurz-Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ebneter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor M\u00e1rk","family":"Somfai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara M.","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Menghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"1305_CR1","doi-asserted-by":"crossref","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et\u00a0al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316. https:\/\/www.thelancet.com\/action\/showFullText?pii=S2214109X13701451.","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"1305_CR2","doi-asserted-by":"crossref","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et\u00a0al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348. https:\/\/pubmed.ncbi.nlm.nih.gov\/23084240\/","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"1305_CR3","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/www.thelancet.com\/action\/showFullText?pii=S0140673622000101."},{"key":"1305_CR4","doi-asserted-by":"crossref","unstructured":"Iglicki M, Gonz\u00e1lez DP, Loewenstein A, Zur D. Longer-acting treatments for neovascular age-related macular degeneration\u2014Present and future. Eye. 2021;35(4):1111. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8115504\/.","DOI":"10.1038\/s41433-020-01309-9"},{"key":"1305_CR5","doi-asserted-by":"crossref","unstructured":"Almony A, Keyloun KR, Shah-Manek B, Multani JK, McGuiness CB, Chen CC, et\u00a0al. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis. J Manag Care Spec Pharm. 2021;27(9):1260\u201372. https:\/\/pubmed.ncbi.nlm.nih.gov\/34464210\/.","DOI":"10.18553\/jmcp.2021.27.9.1260"},{"issue":"1","key":"1305_CR6","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1080\/13696998.2025.2536420","volume":"28","author":"A Ambresin","year":"2025","unstructured":"Ambresin A, Quist SW, Boer M, Maamari S, Barthelmes D. Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland. J Med Econ. 2025;28(1):1198\u2013213. https:\/\/doi.org\/10.1080\/13696998.2025.2536420.","journal-title":"J Med Econ"},{"key":"1305_CR7","doi-asserted-by":"crossref","unstructured":"Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23(2):127\u201340. https:\/\/pubmed.ncbi.nlm.nih.gov\/28064517\/.","DOI":"10.1080\/13548506.2016.1274040"},{"issue":"5","key":"1305_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","volume":"3","author":"PG Traine","year":"2019","unstructured":"Traine PG, Pfister IB, Zandi S, Spindler J, Garweg JG. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a \u201ctreat-and-extend\u201d regimen. Ophthalmol Retina. 2019;3(5):393\u20139. https:\/\/doi.org\/10.1016\/j.oret.2019.01.018.","journal-title":"Ophthalmol Retina"},{"key":"1305_CR9","doi-asserted-by":"crossref","unstructured":"Ebneter A, Michels S, Pruente C, Imesch P, Eilenberger F, Oesch S, et\u00a0al. Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration. Sci Rep. 2020;10(1):1\u20138. https:\/\/www.nature.com\/articles\/s41598-020-76354-1.","DOI":"10.1038\/s41598-020-76354-1"},{"key":"1305_CR10","doi-asserted-by":"crossref","unstructured":"Veritti D, Sarao V, Di Bin F, Lanzetta P. Pharmacokinetic and pharmacodynamic rationale for extending VEGF inhibition increasing intravitreal aflibercept dose. Pharmaceutics. 2023;15(5):1416. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10220677\/.","DOI":"10.3390\/pharmaceutics15051416"},{"key":"1305_CR11","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et\u00a0al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141(9):834\u201342. https:\/\/pubmed.ncbi.nlm.nih.gov\/37535382\/."},{"key":"1305_CR12","doi-asserted-by":"crossref","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et\u00a0al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352. https:\/\/pubmed.ncbi.nlm.nih.gov\/38461841\/.","DOI":"10.1016\/S0140-6736(24)00063-1"},{"key":"1305_CR13","doi-asserted-by":"crossref","unstructured":"Matsumoto H, Hoshino J, Numaga S, Asatori Y, Akiyama H. Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-na\u00efve neovascular age-related macular degeneration. Jpn J Ophthalmol. 2025. https:\/\/pubmed.ncbi.nlm.nih.gov\/40637952\/.","DOI":"10.1007\/s10384-025-01229-9"},{"key":"1305_CR14","doi-asserted-by":"crossref","unstructured":"Cattaneo J, De Oliveira Figueiredo EC, Montesel A, Vermeirsch S, Eandi CM. Early real-world outcomes of intravitreal aflibercept 8\u00a0mg in treatment-Na\u00efve neovascular AMD: AI-assisted fluid volume analysis. Int J Retina Vitreous. 2025;11(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/40200296\/.","DOI":"10.1186\/s40942-025-00665-6"},{"key":"1305_CR15","doi-asserted-by":"crossref","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA. Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol. 2025;10(1):2091. https:\/\/bmjophth.bmj.com\/content\/10\/1\/e002091.","DOI":"10.1136\/bmjophth-2024-002091"},{"key":"1305_CR16","unstructured":"Bala S, Barbosa GCS, Mohan N, Srivastava SK, Kaiser PK, Sastry A, et\u00a0al. Initial functional and anatomical outcomes of high-dose aflibercept 8 mg in exudative neovascular age-related macular degeneration. Ophthalmol Retina. 2025;0(0):1\u201311. https:\/\/www.ophthalmologyretina.org\/action\/showFullText?pii=S2468653025000545."},{"key":"1305_CR17","doi-asserted-by":"crossref","unstructured":"Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Crozat B, Barry MP, et\u00a0al. Early outcome analysis of intravitreal aflibercept 8 mg treatment in na\u00efve patients with neovascular age-related macular degeneration using artificial intelligence. Ophthalmol Ther. 2025. https:\/\/pubmed.ncbi.nlm.nih.gov\/40971062\/.","DOI":"10.1007\/s40123-025-01239-3"},{"issue":"1","key":"1305_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ophtha.2018.08.023","volume":"126","author":"V Nguyen","year":"2019","unstructured":"Nguyen V, Daien V, Guymer R, Young S, Hunyor A, Fraser-Bell S, et\u00a0al. Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration. Ophthalmology. 2019;126(1):64\u201374.","journal-title":"Ophthalmology"},{"key":"1305_CR19","doi-asserted-by":"crossref","unstructured":"Pfister IB, Schild C, Garweg JG. Predicting long-term functional anti-VEGF treatment outcomes in neovascular AMD in a real-world setting. PLoS One. 2024;19(11). https:\/\/pubmed.ncbi.nlm.nih.gov\/39585864\/.","DOI":"10.1371\/journal.pone.0314167"},{"key":"1305_CR20","doi-asserted-by":"crossref","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046\u201350. https:\/\/pubmed.ncbi.nlm.nih.gov\/20559157\/.","DOI":"10.1097\/IAE.0b013e3181d87e04"},{"key":"1305_CR21","doi-asserted-by":"crossref","unstructured":"Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities \u201chand motion\u201d and \u201ccounting fingers\u201d can be quantified with the freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47(3):1236\u201340. https:\/\/pubmed.ncbi.nlm.nih.gov\/16505064\/.","DOI":"10.1167\/iovs.05-0981"},{"key":"1305_CR22","doi-asserted-by":"crossref","unstructured":"Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et\u00a0al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29(6):721\u201331. https:\/\/pubmed.ncbi.nlm.nih.gov\/25882328\/.","DOI":"10.1038\/eye.2015.48"},{"key":"1305_CR23","doi-asserted-by":"crossref","unstructured":"Cho HJ, Park SM, Kim J, Nah SK, Lee J, Lee DW, et\u00a0al. Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Acta Ophthalmol. 2021;99(4):e540\u20136. https:\/\/pubmed.ncbi.nlm.nih.gov\/32996674\/.","DOI":"10.1111\/aos.14631"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01305-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:09:45Z","timestamp":1773151785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01305-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1305"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01305-w","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gabriela Grimaldi: consultant for Apellis, Bayer, and Roche. Lecturer for AbbVie, Apellis, Bayer, and Roche. Grant support from Bayer and Roche. Justus G. Garweg: advisor and speaker for several pharmaceutical companies. Contributes to several international industry-sponsored clinical studies in the fields of retinal disease and uveitis (AbbVie, Bayer, Novartis, Roche, Amgen, MS Pharma). This manuscript is independent of these activities. Sandrine Zweifel: consultant and advisor for Alcon, Allergan, Apellis, Bayer, Endogena, Novartis, Roche, and Zeiss, and grant support from Bayer, Novartis, and Roche, outside the submitted work. Andreas Ebneter: Advisor for Bayer Schweiz AG, Apellis Inc. and Roche Schweiz AG. He is a former employee of F. Hoffmann-La Roche Ltd. G\u00e1bor M. Somfai: consultant for Apellis, Allergan, Bayer, Carl Zeiss, and Roche. Chiara M. Eandi: advisory board participant and lecturer for AbbVie, Apellis, Astellas, Bayer, and Roche. Marion R. Munk: consultant for Abbvie, Allergan, Acucela, Aviceda Therapeutics, Alimera, Bayer, Lumithera, OD-OS, Isarna Therapeutics, Roche, Novartis, Oculis, Ocuterra, genesight Therapeutics, Kubota, B\u00f6hringer-Ingelheim, Eyepoint, Ocular Therapeutix, Apellis, Astellas, Zeiss, RetinAI, and Dandelion. Aude Ambresin: consultant for Bayer, Novartis, Roche, Apellis, and Earlysight; lecturer fees from Optovue, AbbVie, Novartis, Bayer, Roche, Apellis, Astellas, and RetinAi. Moreno Menghini: consultant for Alcon, Apellis, Astellas, Bayer, and Roche. Lecturer for Bayer and Roche. Grant support from Bayer and Roche. Nicol\u00f2 Bartolomeo, Isabel B. Pfister, Christin Schild, Arianna Peyla, Anne Tillmann, Eva Cristina De Oliveira Figueiredo, Tahm Spitznagel, Alice M. Kitay, Felix Gabathuler, and Malaika Mihal Kurz-Levin have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by all participating ethics committees, led by the ethics committee of the canton of Berne (registration no. 2024-01026). Coded patient data were included on the basis of general or specific informed consent, in line with ICH-GCP E6, the Declaration of Helsinki, and Swiss law.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}